User menu

Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia

Bibliographic reference De Viron, Emeline ; Michaux, Lucienne ; Put, Natalie ; Bontemps, Françoise ; Van Den Neste, Eric. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. In: Leukemia and Lymphoma, Vol. 53, no. 8, p. 1445-1451 (2012)
Permanent URL http://hdl.handle.net/2078.1/124282
  1. Chiorazzi Nicholas, Rai Kanti R., Ferrarini Manlio, Chronic Lymphocytic Leukemia, 10.1056/nejmra041720
  2. Dighiero G, Hamblin TJ, Chronic lymphocytic leukaemia, 10.1016/s0140-6736(08)60456-0
  3. Gribben John G., O'Brien Susan, Update on Therapy of Chronic Lymphocytic Leukemia, 10.1200/jco.2010.32.3865
  4. Hallek Michael, Pflug Natali, State of the art treatment of chronic lymphocytic leukaemia, 10.1016/j.blre.2010.09.001
  5. Rao VA, Clin Cancer Res, 9, 3204 (2003)
  6. Rosenwald A., Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response, 10.1182/blood-2003-09-3236
  7. Gandhi Varsha, p53 as a predictor for chemotherapy response in CLL cells, 10.1080/10428190601186028
  8. Zenz Thorsten, Benner Axel, Döhner Hartmut, Stilgenbauer Stephan, Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway, 10.4161/cc.7.24.7245
  9. Zenz Thorsten, Mohr Julia, Edelmann Jennifer, Sarno Antonio, Hoth Patrick, Heuberger Maria, Helfrich Hanne, Mertens Daniel, Döhner Hartmut, Stilgenbauer Stephan, Treatment resistance in chronic lymphocytic leukemia–the role of the p53 pathway, 10.1080/10428190902763533
  10. Zenz Thorsten, Fröhling Stefan, Mertens Daniel, Döhner Hartmut, Stilgenbauer Stephan, Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL), 10.1016/j.beha.2009.12.003
  11. Sturm I, Bosanquet A G, Hermann S, Güner D, Dörken B, Daniel P T, Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy, 10.1038/sj.cdd.4401194
  12. Stilgenbauer S., Sander S., Bullinger L., Benner A., Leupolt E., Winkler D., Krober A., Kienle D., Lichter P., Dohner H., Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival, 10.3324/haematol.10720
  13. Stilgenbauer S., Zenz T., Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia, 10.1182/asheducation-2010.1.481
  14. Zenz T, Nat Rev Cancer, 10, 37 (2010)
  15. Hallek M., Cheson B. D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., Hillmen P., Keating M. J., Montserrat E., Rai K. R., Kipps T. J., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, 10.1182/blood-2007-06-093906
  16. Gryshchenko Irina, Hofbauer Sebastian, Stoecher Markus, Daniel Peter T., Steurer Michael, Gaiger Alexander, Eigenberger Karin, Greil Richard, Tinhofer Inge, MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia, 10.1200/jco.2007.11.5212
  17. Zenz T., Habe S., Denzel T., Mohr J., Winkler D., Buhler A., Sarno A., Groner S., Mertens D., Busch R., Hallek M., Dohner H., Stilgenbauer S., Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial, 10.1182/blood-2009-05-224071
  18. Zenz T., Mohr J., Eldering E., Kater A. P., Buhler A., Kienle D., Winkler D., Durig J., van Oers M. H. J., Mertens D., Dohner H., Stilgenbauer S., miR-34a as part of the resistance network in chronic lymphocytic leukemia, 10.1182/blood-2008-08-172254
  19. Durocher Daniel, Jackson Stephen P, DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?, 10.1016/s0955-0674(00)00201-5
  20. Shiloh Yosef, ATM and related protein kinases: safeguarding genome integrity, 10.1038/nrc1011
  21. Kruse Jan-Philipp, Gu Wei, Modes of p53 Regulation, 10.1016/j.cell.2009.04.050
  22. Wang Zhongfeng, Li Baojie, Mdm2 links genotoxic stress and metabolism to p53, 10.1007/s13238-010-0140-9
  23. Bommer Guido T., Gerin Isabelle, Feng Ying, Kaczorowski Andrew J., Kuick Rork, Love Robert E., Zhai Yali, Giordano Thomas J., Qin Zhaohui S., Moore Bethany B., MacDougald Ormond A., Cho Kathleen R., Fearon Eric R., p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes, 10.1016/j.cub.2007.06.068
  24. Riley Todd, Sontag Eduardo, Chen Patricia, Levine Arnold, Transcriptional control of human p53-regulated genes, 10.1038/nrm2395
  25. Beckerman R., Prives C., Transcriptional Regulation by P53, 10.1101/cshperspect.a000935
  26. Feng Z., Zhang C., Wu R., Hu W., Tumor suppressor p53 meets microRNAs, 10.1093/jmcb/mjq040
  27. Liang Yulong, Lin Shiaw-Yih, Brunicardi F. Charles, Goss John, Li Kaiyi, DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment, 10.1007/s00268-008-9840-1
  28. Meek DW, Nat Rev Cancer, 9, 714 (2009)
  29. Ozaki Toshinori, Nakagawara Akira, p53: The Attractive Tumor Suppressor in the Cancer Research Field, 10.1155/2011/603925
  30. Wattel E, Blood, 84, 3148 (1994)
  31. Dohner H, Blood, 85, 1580 (1995)
  32. Döhner Hartmut, Stilgenbauer Stephan, Benner Axel, Leupolt Elke, Kröber Alexander, Bullinger Lars, Döhner Konstanze, Bentz Martin, Lichter Peter, Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, 10.1056/nejm200012283432602
  33. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V., Cejkova S., Svitakova M., Skuhrova Francova H., Brychtova Y., Doubek M., Brejcha M., Klabusay M., Mayer J., Pospisilova S., Trbusek M., Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage, 10.1182/blood-2009-07-234708
  34. Zenz Thorsten, Mertens Daniel, Döhner Hartmut, Stilgenbauer Stephan, Importance of genetics in chronic lymphocytic leukemia, 10.1016/j.blre.2011.02.002
  35. Zenz T., Krober A., Scherer K., Habe S., Buhler A., Benner A., Denzel T., Winkler D., Edelmann J., Schwanen C., Dohner H., Stilgenbauer S., Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up, 10.1182/blood-2008-04-154070
  36. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C, The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype, 10.1038/leu.2008.274
  37. Rossi D., Cerri M., Deambrogi C., Sozzi E., Cresta S., Rasi S., De Paoli L., Spina V., Gattei V., Capello D., Forconi F., Lauria F., Gaidano G., The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness, 10.1158/1078-0432.ccr-08-1630
  38. Zenz Thorsten, Eichhorst Barbara, Busch Raymonde, Denzel Tina, Häbe Sonja, Winkler Dirk, Bühler Andreas, Edelmann Jennifer, Bergmann Manuela, Hopfinger Georg, Hensel Manfred, Hallek Michael, Döhner Hartmut, Stilgenbauer Stephan, TP53Mutation and Survival in Chronic Lymphocytic Leukemia, 10.1200/jco.2009.27.8762
  39. Gonzalez David, Martinez Pilar, Wade Rachel, Hockley Sarah, Oscier David, Matutes Estella, Dearden Claire E., Richards Sue M., Catovsky Daniel, Morgan Gareth J., Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial, 10.1200/jco.2010.32.0838
  40. Saddler C., Ouillette P., Kujawski L., Shangary S., Talpaz M., Kaminski M., Erba H., Shedden K., Wang S., Malek S. N., Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia, 10.1182/blood-2007-09-112698
  41. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P, Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial, 10.1016/s0140-6736(07)61125-8
  42. Grever Michael R., Lucas David M., Dewald Gordon W., Neuberg Donna S., Reed John C., Kitada Shinichi, Flinn Ian W., Tallman Martin S., Appelbaum Frederick R., Larson Richard A., Paietta Elisabeth, Jelinek Diane F., Gribben John G., Byrd John C., Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997, 10.1200/jco.2006.08.3089
  43. Turgut Burhan, Vural Ozden, Pala Funda S., Pamuk Gülsüm E., TabakcioĞlu Kiymet, Demir Muzaffer, Öngören Şeniz, Soysal Teoman, Algüneş Çetin, 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis, 10.1080/10428190601059829
  44. Trbusek Martin, Smardova Jana, Malcikova Jitka, Sebejova Ludmila, Dobes Petr, Svitakova Miluse, Vranova Vladimira, Mraz Marek, Francova Hana Skuhrova, Doubek Michael, Brychtova Yvona, Kuglik Petr, Pospisilova Sarka, Mayer Jiri, Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia, 10.1200/jco.2011.34.7872
  45. Fegan C, Leukemia, 9, 2003 (1995)
  46. Dohner H, Blood, 89, 2516 (1997)
  47. Stankovic T., Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage, 10.1182/blood.v99.1.300
  48. Austen Belinda, Skowronska Anna, Baker Claire, Powell Judith E., Gardiner Anne, Oscier David, Majid Aneela, Dyer Martin, Siebert Reiner, Taylor A. Malcolm, Moss Paul A., Stankovic Tatjana, Mutation Status of the ResidualATMAllele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion, 10.1200/jco.2007.11.2649
  49. Austen B., Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL, 10.1182/blood-2004-11-4516
  50. Cejkova Sona, Rocnova Ludmila, Potesil David, Smardova Jana, Novakova Vera, Chumchalova Jitka, Zezulkova Dita, Borsky Marek, Doubek Michael, Brychtova Yvona, Pospisilova Sarka, Klabusay Martin, Mayer Jiri, Trbusek Martin, Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine, 10.1111/j.1600-0609.2008.01177.x
  51. Tsimberidou Apostolia-Maria, Tam Constantine, Abruzzo Lynne V., O'Brien Susan, Wierda William G., Lerner Susan, Kantarjian Hagop M., Keating Michael J., Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia, 10.1002/cncr.23993
  52. Stilgenbauer Stephan, Zenz Thorsten, Winkler Dirk, Bühler Andreas, Schlenk Richard F., Groner Silja, Busch Raymonde, Hensel Manfred, Dührsen Ulrich, Finke Jürgen, Dreger Peter, Jäger Ulrich, Lengfelder Eva, Hohloch Karin, Söling Ulrike, Schlag Rudolf, Kneba Michael, Hallek Michael, Döhner Hartmut, Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group, 10.1200/jco.2008.21.1128
  53. Valganon Mikel, Giraldo Pilar, Agirre Xabier, Larrayoz Maria J., Rubio-Martinez Araceli, Rubio-Felix Daniel, Calasanz Maria J., Odero Maria D., p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV, 10.1111/j.1365-2141.2005.05405.x
  54. Konikova E, Neoplasma, 50, 31 (2003)
  55. Baran-Marszak F., Differential roles of STAT1  and STAT1  in fludarabine-induced cell cycle arrest and apoptosis in human B cells, 10.1182/blood-2003-10-3508
  56. Romanov Vadim V, James Christine H, Sherrington Paul D, Pettitt Andrew R, Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia, 10.1038/sj.onc.1208895
  57. Willander Kerstin, Ungerbäck Jonas, Karlsson Karin, Fredrikson Mats, Söderkvist Peter, Linderholm Mats, MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia : MDM2 SNP309 and B-CLL, 10.1111/j.1600-0609.2010.01470.x
  58. Asslaber D., Pinon J. D., Seyfried I., Desch P., Stocher M., Tinhofer I., Egle A., Merkel O., Greil R., microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia, 10.1182/blood-2009-07-234823
  59. Merkel Olaf, Asslaber Daniela, Pinon Josefina, Egle Alexander, Greil Richard, Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia, 10.4161/cc.9.14.12267
  60. Chang Tsung-Cheng, Wentzel Erik A., Kent Oliver A., Ramachandran Kalyani, Mullendore Michael, Lee Kwang Hyuck, Feldmann Georg, Yamakuchi Munekazu, Ferlito Marcella, Lowenstein Charles J., Arking Dan E., Beer Michael A., Maitra Anirban, Mendell Joshua T., Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes Apoptosis, 10.1016/j.molcel.2007.05.010
  61. Tarasov Valery, Jung Peter, Verdoodt Berlinda, Lodygin Dmitri, Epanchintsev Alexey, Menssen Antje, Meister Gunter, Hermeking Heiko, Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest, 10.4161/cc.6.13.4436
  62. Yamakuchi M., Ferlito M., Lowenstein C. J., miR-34a repression of SIRT1 regulates apoptosis, 10.1073/pnas.0801613105
  63. Jones GG, Leuk Lymphoma, 46, S56 (2005)
  64. Johnson G. G., Sherrington P. D., Carter A., Lin K., Liloglou T., Field J. K., Pettitt A. R., A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene, 10.1158/0008-5472.can-09-0627
  65. Lee J. Y., Yu S. J., Park Y. G., Kim J., Sohn J., Glycogen Synthase Kinase 3  Phosphorylates p21WAF1/CIP1 for Proteasomal Degradation after UV Irradiation, 10.1128/mcb.01461-06
  66. Bastin-Coyette L., Cardoen S., Smal C., de Viron E., Arts A., Amsailale R., Van Den Neste E., Bontemps F., Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines, 10.1016/j.bcp.2010.12.009
  67. Starczynski Jane, Pepper Chris, Pratt Guy, Hooper Laura, Thomas Alun, Milligan Donald, Bentley Paul, Fegan Christopher, Common Polymorphism G(-248)A in the Promoter Region of thebaxGene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated, 10.1200/jco.2005.02.192
  68. Syed N., Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies, 10.1182/blood-2005-03-1194
  69. Buggins Andrea G.S., Pepper Chris J., The role of Bcl-2 family proteins in chronic lymphocytic leukaemia, 10.1016/j.leukres.2010.03.011
  70. Iliakis George, Wang Ya, Guan Jun, Wang Huichen, DNA damage checkpoint control in cells exposed to ionizing radiation, 10.1038/sj.onc.1206682
  71. Heisig P., Type II topoisomerases--inhibitors, repair mechanisms and mutations, 10.1093/mutage/gep035
  72. Rastogi Rajesh P., Richa, Kumar Ashok, Tyagi Madhu B., Sinha Rajeshwar P., Molecular Mechanisms of Ultraviolet Radiation-Induced DNA Damage and Repair, 10.4061/2010/592980
  73. Van den Neste E, Int J Oncol, 27, 1113 (2005)
  74. Ewald B, Sampath D, Plunkett W, Nucleoside analogs: molecular mechanisms signaling cell death, 10.1038/onc.2008.316
  75. Robak Tadeusz, Korycka Anna, Lech-Maranda Ewa, Robak Pawel, Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases, 10.3390/molecules14031183
  76. Kojima K., Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia, 10.1182/blood-2005-12-5148
  77. Secchiero P., Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL), 10.1182/blood-2005-11-4465
  78. Bixby Dale, Kujawski Lisa, Wang Shaomeng, Malek Sami N., The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis, 10.4161/cc.7.8.5754
  79. Jones Gillian G, Reaper Philip M, Pettitt Andrew R, Sherrington Paul D, The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes, 10.1038/sj.onc.1207318
  80. Le Garff-Tavernier M, Blood Cancer J, 1 (2011)
  81. Carter A., Lin K., Sherrington P. D., Pettitt A. R., Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia, 10.1111/j.1365-2141.2004.05223.x
  82. Carter A, Lin K, Sherrington P D, Atherton M, Pearson K, Douglas A, Burford A, Brito-Babapulle V, Matutes E, Catovsky D, Pettitt A R, Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia, 10.1038/sj.leu.2404120
  83. Mohr J., Helfrich H., Fuge M., Eldering E., Buhler A., Winkler D., Volden M., Kater A. P., Mertens D., Te Raa D., Dohner H., Stilgenbauer S., Zenz T., DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing, 10.1182/blood-2010-08-300160
  84. Pettitt A. R., p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation, 10.1182/blood.v98.3.814
  85. Mackus W J M, Kater A P, Grummels A, Evers L M, Hooijbrink B, Kramer M H H, Castro J E, Kipps T J, van Lier R A W, van Oers M H J, Eldering E, Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation, 10.1038/sj.leu.2403623
  86. de Viron Emeline, Knoops Laurent, Connerotte Thierry, Smal Caroline, Michaux Lucienne, Saussoy Pascale, Vannuffel Pascal, Beert Eline, Vekemans Marie-Christiane, Hermans C��dric, Bontemps Fran��oise, Van Den Neste Eric, Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response, 10.1111/j.1365-2141.2009.07900.x
  87. Mous R, Jaspers A, Luijks D M P, Mellink C H M, van Oers M H J, Kater A P, Eldering E, Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction, 10.1038/leu.2009.71
  88. Stankovic T., Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses, 10.1182/blood-2003-04-1161
  89. Dijkstra M K, van Lom K, Tielemans D, Elstrodt F, Langerak A W, van ‘t Veer M B, Jongen-Lavrencic M, 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation, 10.1038/leu.2008.264
  90. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S, miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities, 10.1038/leu.2008.377
  91. Rossi S., Shimizu M., Barbarotto E., Nicoloso M. S., Dimitri F., Sampath D., Fabbri M., Lerner S., Barron L. L., Rassenti L. Z., Jiang L., Xiao L., Hu J., Secchiero P., Zauli G., Volinia S., Negrini M., Wierda W., Kipps T. J., Plunkett W., Coombes K. R., Abruzzo L. V., Keating M. J., Calin G. A., microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival, 10.1182/blood-2010-01-263889
  92. di Iasio MG, Invest New Drugs (2011)
  93. Best O G, Gardiner A C, Majid A, Walewska R, Austen B, Skowronska A, Ibbotson R, Stankovic T, Dyer M J S, Oscier D G, A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL, 10.1038/sj.leu.2405092
  94. Best O G, Gardiner A C, Davis Z A, Tracy I, Ibbotson R E, Majid A, Dyer M J S, Oscier D G, A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease, 10.1038/leu.2008.260
  95. Pettitt AR, Haematologica, 92, 0910 (2007)
  96. Zenz T, Häbe S, Denzel T, Winkler D, Döhner H, Stilgenbauer S, How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance, 10.1038/leu.2008.114
  97. Lin K., Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia, 10.1182/blood-2001-11-0066
  98. Vogelstein Bert, Lane David, Levine Arnold J., Surfing the p53 network, 10.1038/35042675
  99. Lin K, Paper presented at NCRI Cancer Conference (2010)
  100. Pettitt, Sherrington, Cawley, The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia, 10.1046/j.1365-2141.1999.01649.x
  101. Lin K., High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment, 10.1182/blood-2003-04-1289
  102. Willmore E., Elliott S. L., Mainou-Fowler T., Summerfield G. P., Jackson G. H., O'Neill F., Lowe C., Carter A., Harris R., Pettitt A. R., Cano-Soumillac C., Griffin R. J., Cowell I. G., Austin C. A., Durkacz B. W., DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia, 10.1158/1078-0432.ccr-07-5158
  103. Sampath D., Calin G. A., Puduvalli V. K., Gopisetty G., Taccioli C., Liu C.-G., Ewald B., Liu C., Keating M. J., Plunkett W., Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation, 10.1182/blood-2008-09-178707